DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics and since July 2021, it is active in the Life Science business.
| FactSnippet No. 954,413 |
DiaSorin offers diagnostic assays employing two of the most common technologies in in vitro diagnostics: immunodiagnostics and molecular diagnostics.
| FactSnippet No. 954,414 |
DiaSorin focuses on the development of research and laboratory kits in the field of molecular diagnostics, particularly specializing in the infectious diseases sector with tests that use different matrices including blood, cerebrospinal fluid, cutaneous and mucus swabs.
| FactSnippet No. 954,415 |
DiaSorin focuses its efforts on several fields of immunodiagnostics: infectious diseases, bone and mineral, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmunity and brain and cardiac markers.
| FactSnippet No. 954,416 |
In 2021 DiaSorin entered into the Life Science space, through the acquisition of Luminex Corporation, gaining access to its Multi-Analyte Profiling technology and to its Flow Cytometry business.
| FactSnippet No. 954,417 |
DiaSorin develops, manufactures and markets tests for the diagnosis of infectious diseases or hormonal disorders.
| FactSnippet No. 954,418 |
In immunodiagnostics, DiaSorin offers the market proprietary-based platforms on the CLIA and ELISA technologies.
| FactSnippet No. 954,419 |
In molecular diagnostics, DiaSorin offers proprietary platforms that cover the three phases of the testing process: extraction, amplification and detection.
| FactSnippet No. 954,420 |
In 2002 DiaSorin acquired BYC Sangtec and the rights to the Liaison platform.
| FactSnippet No. 954,421 |
In 2020 DiaSorin signed an exclusive license agreement with TTP for the automation of molecular diagnostic tests on a Point-of-Care platform.
| FactSnippet No. 954,423 |
On 14 July 2021 DiaSorin announced the completion of the acquisition of Luminex Corporation.
| FactSnippet No. 954,424 |
On 7 April 2020, DiaSorin announced the development of a new IgG CLIA test to identify antibodies against SARS-CoV-2 antibody, test that allows to detect antibodies directed against the virus in patients' serum samples, identifying subjects who have developed an immune response to the virus, offering a tool for epidemiologic assessment of populations.
| FactSnippet No. 954,425 |
On 25 April 2020, DiaSorin received Emergency Use Authorization from the U S Food and Drug Administration for a new serologic test for COVID-19.
| FactSnippet No. 954,426 |
On June 30, DiaSorin announced the launch of the new LIAISON SARS-CoV-2 IgM test, CE marked and made available in the United States through the validation notification submitted to the Food and Drug Administration, which was followed by the authorization request for emergency use, as required by the "Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency ".
| FactSnippet No. 954,427 |
The technologies of immunodiagnostics and molecular diagnostics applied to the tests of DiaSorin are based on automated technological platforms developed by partner companies based on specifications indicated by DiaSorin.
| FactSnippet No. 954,428 |
Areas of DiaSorin's offer for analysis kits in the specialty immunodiagnostics sector are the following:.
| FactSnippet No. 954,429 |
In particular, in the field of molecular diagnostics, DiaSorin has focused its research on the area of infectious diseases, with tests based on different matrices—including blood, cerebrospinal fluid, skin, and mucocutaneous swabs.
| FactSnippet No. 954,430 |
Over time, DiaSorin has entered into partnerships to develop joint business lines.
| FactSnippet No. 954,431 |
DiaSorin has been listed on the Italian Stock Exchange since 2007 and is in the FTSE Italy Mid Cap Index.
| FactSnippet No. 954,432 |